Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors

Dermatology

Volumn 227, Issue 4, 2014, Pages 289-294

  Alter, M ^a   Satzger, I ^a   Mattern, A ^a   Kapp, A ^a   Gutzmer, R ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Dermatooncology; Epidermal growth factor receptor; Medical tumor therapy; Skin cancer; Squamous cell carcinoma

Indexed keywords

ANTIBIOTIC AGENT; CETUXIMAB; CISPLATIN; CYCLOSPORIN; DOXYCYCLINE; ETRETIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; ADVANCED CANCER; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CARDIAC GRAFT REJECTION; CASE REPORT; EXCISION; FEMALE; HEART INFARCTION; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PAPULE; PRIORITY JOURNAL; PUSTULE; RADIATION FIELD; RASH; REVIEW; SATELLITE METASTASIS; SKIN CARCINOMA; VERY ELDERLY; WOUND HEALING; ANTIBIOTIC THERAPY; CANCER REGRESSION; COMPUTER ASSISTED TOMOGRAPHY; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPITHELIZATION; INOPERABLE CANCER; THORAX RADIOGRAPHY; TOPICAL TREATMENT; TREATMENT RESPONSE;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SCALP; SKIN NEOPLASMS;

EID: 84892142860     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000355181     Document Type: Review

References (36)

1. Diepgen TL, Mahler V: The epidemiology of skin cancer. Br J Dermatol 2002; 146(suppl 61):1-6.
2. Brantsch K, Sotlar K, Brod C, Breuninger H: Metastatic basosquamous carcinoma: report of two cases. Dermatol Surg 2008; 34: 1738-1741.
3. Cranmer LD, Engelhardt C, Morgan SS: Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 2010; 15: 1320-1328.
4. Breuninger H, Bootz F, Hauschild A, Kortmann RD, Wolff K, Stockfleth E, et al: Short German guidelines: squamous cell carcinoma. J Dtsch Dermatol Ges 2008; 6(suppl 1): S5-S8.
5. Wollina U, Hansel G, Koch A, Kostler E: Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol 2005; 131: 300-304.
6. Fogarty GB, Conus NM, Chu J, McArthur G: Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol 2007; 156: 92-98.
7. Kikuchi A, Amagai M, Hayakawa K, Ueda M, Hirohashi S, Shimizu N, et al: Association of EGF receptor expression with proliferating cells and of ras p21 expression with differentiating cells in various skin tumours. Br J Dermatol 1990; 123: 49-58.
8. Shimizu T, Izumi H, Oga A, Furumoto H, Murakami T, Ofuji R, et al: Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology 2001; 202: 203-206.
9. Krahn G, Leiter U, Kaskel P, Udart M, Utikal J, Bezold G, et al: Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer 2001; 37: 251-259.
10. Toll A, Salgado R, Yebenes M, Martin-Ezquerra G, Gilaberte M, Baro T, et al: Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas. Exp Dermatol 2010; 19: 151-153.
11. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al: Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29: 3419-3426.
12. Ch'ng S, Low I, Ng D, Brasch H, Sullivan M, Davis P, Tan ST: Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol 2008; 39: 344-349.
13. Nazmi MN, Dykes PJ, Marks R: Epidermal growth factor receptors in human epidermal tumours. Br J Dermatol 1990; 123: 153-161.
14. Lavrijsen AP, Tieben LM, Ponec M, van der Schroeff JG, van Muijen GN: Expression of EGF receptor, involucrin, and cytokeratins in basal cell carcinomas and squamous cell carcinomas of the skin. Arch Dermatol Res 1989; 281: 83-88.
15. Mauerer A, Herschberger E, Dietmaier W, Landthaler M, Hafner C: Low incidence of EGFR and HRAS mutations in cutaneous squamous cell carcinomas of a German cohort. Exp Dermatol 2011; 20: 848-850.
16. Ridd K, Bastian BC: Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma. J Invest Dermatol 2010; 130: 901-903.
17. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
18. Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, Garcia-Saenz JA, Cruz-Hernandez JJ, et al: Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 2012; 23: 1016-1022.
19. Buchanan FG, Wang D, Bargiacchi F, DuBois RN: Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003; 278: 35451-35457.
20. Xu K, Shu HK: EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res 2007; 67: 6121-6129.
21. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS: Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8: 289-293.
22. Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G, Wagner SN: Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 2008; 6: 1066-1069.
23. Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, et al: A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 2012; 18: 1435-1446.
24. Engelhardt C, Curiel-Lewandrowski C, Warneke J, Cranmer L: Metastatic cutaneous squamous cell carcinoma responding to erlotinib therapy. J Am Acad Dermatol 2011; 65: 237-238.
25. Wollina U: Cetuximab in non-melanoma skin cancer. Expert Opin Biol Ther 2012; 12: 949-956.
26. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
27. Reck M, Gutzmer R: Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition. Onkologie 2010; 33: 470-479.
28. Leard LE, Cho BK, Jones KD, Hays SR, Tope WD, Golden JA, et al: Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant 2007; 26: 1340-1344.
29. Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K: Cetuximab in refractory skin cancer treatment. J Cancer 2012; 3: 257-261.
30. Bauman JE, Eaton KD, Martins RG: Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 2007; 143: 889-892.
31. Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH: Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology 2009; 219: 80-83.
32. Miller K, Sherman W, Ratner D: Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma. Dermatol Surg 2010; 36: 2069-2074.
33. Giacchero D, Barriere J, Benezery K, Guillot B, Dutriaux C, Mortier L, et al: Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma - a report of eight cases. Clin Oncol (R Coll Radiol) 2011; 23: 716-718.
34. Suen JK, Bressler L, Shord SS, Warso M, Villano JL: Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs 2007; 18: 827-829.
35. Rubio Casadevall J, Grana-Suarez B, Hernandez-Yague X, Vayreda Ribera J, Huc Grasa O, Brunet Vidal J: Xeroderma pigmentosum: neck lymph node metastasis of a squamous cell carcinoma of the skin treated with cetuximab. Eur J Dermatol 2009; 19: 163-165.
36. Kim S, Eleff M, Nicolaou N: Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. Head Neck 2011; 33: 286-288.